Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

ema.europa.eu

Orphan designations

Get the latest updates from Orphan designations directly as they happen.

Follow now 178 followers

Latest posts

Last updated 14 days ago

Orphan designation: (14S)-8-[3-(2-{dispiro[2.0.24.13]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2lamba6-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate, deutivaca

14 days ago

Orphan designation: (14S)-8-[3-(2-{dispiro[2.0.24.13]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2lamba6-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate, deutivacaftor, tezacaftor Treatment of cystic fibrosis...

Orphan designation: diflunisal Treatment of ATTR amyloidosis, 21/06/2022 Positive

14 days ago

Orphan designation: diflunisal Treatment of ATTR amyloidosis, 21/06/2022 Positive

Orphan designation: Zanidatamab Treatment of biliary tract cancer, 19/07/2021 Positive

14 days ago

Orphan designation: Zanidatamab Treatment of biliary tract cancer, 19/07/2021 Positive

Orphan designation: (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one Treatment of hyperphenylalaninemia, 20/05/2021 Positive

14 days ago

Orphan designation: (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one Treatment of hyperphenylalaninemia, 20/05/2021 Positive

Orphan designation: Unesbulin Treatment of soft tissue sarcoma, 10/12/2021 Withdrawn

about 1 month ago

Orphan designation: Unesbulin Treatment of soft tissue sarcoma, 10/12/2021 Withdrawn

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

about 1 month ago

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn

about 1 month ago

Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn

Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive

about 1 month ago

Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive

Orphan designation: allopurinol Treatment of Marfan syndrome, 25/03/2025 Positive

about 1 month ago

Orphan designation: allopurinol Treatment of Marfan syndrome, 25/03/2025 Positive